Science News

Nature Medicine, Published online: 11 September 2026; doi:10.1038/s41591-026-04642-w In the randomized phase 2 ImmunoPRISM trial, patients with high-risk smoldering multiple myeloma (MM) showed higher rates of complete clinical responses in response to treatment with teclistamab compared with lenalidomide–dexamethasone, although longer follow-up is required to determine durable prevention of progression to MM. Read More

Science News

Nature Medicine, Published online: 11 September 2026; doi:10.1038/s41591-026-04635-9 A 15-year cohort study shows that Alzheimer’s dementia risk is jointly shaped by Alzheimer’s pathology and cognitive resilience, with high resilience linked to lower risk, even under greater pathology. Read More